Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

被引:0
|
作者
Silberg, Matteo [2 ]
Krabbe, Laura-Maria [3 ]
Boegemann, Martin [1 ]
Schrader, Andres Jan [1 ]
Tully, Karl [2 ]
Schlack, Katrin [1 ]
机构
[1] Univ Hosp Muenster, Dept Urol, Munster, Germany
[2] Ruhr Univ Bochum, Univ Hosp, Marien Hosp Herne, Dept Urol, Hoelkeskampring 40, D-44625 Herne, Germany
[3] Vivantes Network Hlth, Dept Urol, Berlin, Germany
关键词
CRITERIA;
D O I
10.1016/j.clgc.2024.102164
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Different combination therapies using anti - PD-1 / PD-L1 or CTLA-4 immune checkpoint inhibition (ICI) are widely used in patients with metastatic renal cell carcinoma (mRCC). In the absents of established biomarkers, immune-related adverse events (irAEs) have been discussed as potential predictors of response. Methods In this retrospective cohort study, data of 134 patients with mRCC undergoing ICI treatment (Nivolumab, Ipilimumab and Nivolumab, Pembrolizumab and Axitinib or Avelumab and Axitinib) between 2015 and 2021 were analyzed. To examine the utility of irAEs as predictors of overall survival (OS) and progression-free survival (PFS), separate Kaplan-Meier analyses and Cox proportional regression analyses were applied. Landmark analysis was conducted after 12 weeks to reduce immortal time bias. Result irAEs were observed in 85 patients (63.4%). Cutaneous (n = 52, 38.8%), endocrine (n = 33, 24.6%) and hepatic (n = 19, 14.2%) irAEs were most commonly observed. In Kaplan-Meier analysis, patients experiencing irAEs showed favorable median PFS (15 months, 95% CI, 9.91-20.09) compared to the non-irAE group (5 months, 95% CI, 3.56-6.44, P < .001). The median OS was 25 months (95% CI, 16.79-33.21) in the non-irAE group, while it was not reached in the irAE group (P = .002). In multivariable analysis, the presence of any irAE was associated with favorable PFS (HR 0.46 [95% CI, 0.26-0.82] P = .008) and OS (HR: 0.28 [95% CI, 0.12-0.63] P = .002), respectively. Landmark analysis after 12 weeks showed mixed results depending on the classification of the irAE group at the landmark time. Conclusion The presence of irAEs under ICI therapy in patients with mRCC is associated with better PFS and OS. Thus, manageable irAEs should not be cause for premature discontinuation of ICI therapy, as they seem to indicate favorable outcomes. Considering the time-dependent nature of irAEs is crucial estimating their value as predictive markers.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Immune-related adverse events can predict progression-free and overall survival in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors
    Silberg, Matteo
    Krabbe, Laura-Maria
    Boegemann, Martin
    Schrader, Andres Jan
    Schlack, Katrin
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 103 - 103
  • [2] Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
    Martini, Dylan J.
    Goyal, Subir
    Liu, Yuan
    Evans, Sean T.
    Olsen, T. Anders
    Case, Katherine
    Magod, Benjamin L.
    Brown, Jacqueline T.
    Yantorni, Lauren
    Russler, Greta Anne
    Caulfield, Sarah
    Goldman, Jamie M.
    Nazha, Bassel
    Harris, Wayne B.
    Kissick, Haydn T.
    Master, Viraj A.
    Kucuk, Omer
    Carthon, Bradley C.
    Bilen, Mehmet Asim
    [J]. ONCOLOGIST, 2021, 26 (10): : E1742 - E1750
  • [3] Noncutaneous immune-related adverse events predict overall and progression-free survival in patients with cutaneous toxicities after immune checkpoint inhibitor therapy
    Asdourian, Maria S.
    Jacoby, Ted V.
    Shah, Nishi
    Otto, Tracey
    Thompson, Leah L.
    Dee, Edward Christopher
    Reynolds, Kerry L.
    Semenov, Yevgeniy R.
    Chen, Steven T.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (06) : 1368 - 1370
  • [4] Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
    Cook, Sarah
    Samuel, Vanessa
    Meyers, Daniel E.
    Stukalin, Igor
    Litt, Ishjot
    Sangha, Randeep
    Morris, Don G.
    Heng, Daniel Y. C.
    Pabani, Aliyah
    Dean, Michelle
    Navani, Vishal
    [J]. JAMA NETWORK OPEN, 2024, 7 (01) : E2352302
  • [5] Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors
    Foster, Corey C.
    Couey, Marcus A.
    Kochanny, Sara E.
    Khattri, Arun
    Acharya, Rajesh K.
    Tan, Yi-Hung Carol
    Brisson, Ryan J.
    Leidner, Rom S.
    Seiwert, Tanguy Y.
    [J]. CANCER, 2021, 127 (24) : 4565 - 4573
  • [6] Risk Factors of Immune Related Adverse Events in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
    Chehade, Razane El Hajj
    Semaan, Karl
    Saliby, Renee Maria
    Saad, Eddy
    Nawfal, Rashad
    Machaalani, Marc
    Eid, Marc
    Yekeduz, Emre
    Steiner, Clara
    Sun, Maxine
    Kaymakcalan, Marina
    Choueiri, Toni K.
    [J]. ONCOLOGIST, 2024, 29
  • [7] Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
    Herrmann, Sandra M.
    Perazella, Mark A.
    [J]. KIDNEY INTERNATIONAL REPORTS, 2020, 5 (08): : 1139 - 1148
  • [8] Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
    Paderi, Agnese
    Giorgione, Roberta
    Giommoni, Elisa
    Mela, Marinella Micol
    Rossi, Virginia
    Doni, Laura
    Minervini, Andrea
    Carini, Marco
    Pillozzi, Serena
    Antonuzzo, Lorenzo
    [J]. CANCERS, 2021, 13 (04) : 1 - 11
  • [9] Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors
    Immanuel Augustin Oppolzer
    Josef Riester
    Roland Büttner
    Maximilian Burger
    Marco Julius Schnabel
    [J]. International Urology and Nephrology, 2023, 55 : 1943 - 1949
  • [10] Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors
    Oppolzer, Immanuel Augustin
    Riester, Josef
    Buettner, Roland
    Burger, Maximilian
    Schnabel, Marco Julius
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2023, 55 (08) : 1943 - 1949